The first of those drugs, Enhertu, succeeded in several key trials and, in the process, changed how certain breast cancers ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback